Literature DB >> 16485178

Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's disease.

Stefan J Teipel1, Harald Hampel.   

Abstract

Aging in Down syndrome (DS) is accompanied by neuropathological features of Alzheimer's disease (AD). Therefore, DS has been proposed as a model to study predementia stages of AD. MRI-based measurement of grey matter atrophy is an in vivo surrogate marker of regional neuronal density. A range of neuroimaging studies have described the macroscopic neuroanatomy of DS. Recent studies using sensitive quantitative measures of region-specific atrophy based on high-resolution MRI suggest that age-related atrophy in DS resembles the pattern of brain atrophy in early stages of AD. The pattern of atrophy determined in predementia DS supports the notion that AD-type pathology leads to neuronal degeneration not only in allocortical, but also in neocortical brain areas before onset of clinical dementia. This has major implications for our understanding of the onset and progression of AD-type pathology both in DS and in sporadic AD.

Entities:  

Mesh:

Year:  2006        PMID: 16485178     DOI: 10.1007/s10519-006-9047-x

Source DB:  PubMed          Journal:  Behav Genet        ISSN: 0001-8244            Impact factor:   2.805


  46 in total

1.  Event-related potential index of age-related differences in memory processes in adults with Down syndrome.

Authors:  Alexandra P Key; Elisabeth M Dykens
Journal:  Neurobiol Aging       Date:  2013-08-29       Impact factor: 4.673

2.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

3.  Complexity of force output during static exercise in individuals with Down syndrome.

Authors:  Kevin S Heffernan; Jacob J Sosnoff; Edward Ofori; Sae Young Jae; Tracy Baynard; Scott R Collier; Stella Goulopoulou; Arturo Figueroa; Jeffrey A Woods; Kenneth H Pitetti; Bo Fernhall
Journal:  J Appl Physiol (1985)       Date:  2009-01-22

4.  White matter involvement in young non-demented Down's syndrome subjects: a tract-based spatial statistic analysis.

Authors:  Andrea Romano; Marta Moraschi; Riccardo Cornia; Alessandro Bozzao; Maria Camilla Rossi-Espagnet; Federico Giove; Giorgio Albertini; Alberto Pierallini
Journal:  Neuroradiology       Date:  2018-09-27       Impact factor: 2.804

5.  Age effects on cortical thickness in young Down's syndrome subjects: a cross-sectional gender study.

Authors:  Andrea Romano; Marta Moraschi; Riccardo Cornia; Alessandro Bozzao; Olga Gagliardo; Laura Chiacchiararelli; Cristina Iani; Giacomo Stella; Giorgio Albertini; Alberto Pierallini
Journal:  Neuroradiology       Date:  2015-01-06       Impact factor: 2.804

Review 6.  Down syndrome, beta-amyloid and neuroimaging.

Authors:  Elizabeth Head; Alex M Helman; David Powell; Frederick A Schmitt
Journal:  Free Radic Biol Med       Date:  2017-09-19       Impact factor: 7.376

Review 7.  Novel MRI techniques in the assessment of dementia.

Authors:  Stefan J Teipel; Thomas Meindl; Lea Grinberg; Helmut Heinsen; Harald Hampel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

8.  Regional cortical volumes and congenital heart disease: a MRI study in 22q11.2 deletion syndrome.

Authors:  Marie Schaer; Bronwyn Glaser; Marie-Christine Ottet; Maude Schneider; Meritxell Bach Cuadra; Martin Debbané; Jean-Philippe Thiran; Stephan Eliez
Journal:  J Neurodev Disord       Date:  2010-09-14       Impact factor: 4.025

9.  Influence of additional weight on the frequency of kicks in infants with Down syndrome and infants with typical development.

Authors:  Gabriela L Santos; Thaís B Bueno; Eloisa Tudella; Jadiane Dionisio
Journal:  Braz J Phys Ther       Date:  2014-06-24       Impact factor: 3.377

10.  Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.

Authors:  Maruan Hijazi; José M Medina; Ana Velasco
Journal:  Mol Neurobiol       Date:  2016-01-23       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.